Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous ...

The team from Doylestown Health's Vascular Surgery is the first in the greater Philadelphia region to use the Abbott ...

Polymer-free stents show comparable PCI results but with increased early thrombosis risk, impacting clinical choices.

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...

Hyderabad: NATCO Pharma Limited, an Indian pharmaceutical company, has announced the approval of its Abbreviated New Drug ...

The approval is for the Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS) of ...

Natco Pharma announced approval of its ANDA for Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation. NATCO's ...